A Machine Learning-based Estimated Survival Model

Status Active, not recruiting

Clinical Trial Summary

Malignant tumors are the leading cause of death in elderly patients, and palliative care can improve the quality of life for elderly advanced cancer patients. One of the main reasons why these patients are not included in palliative care is the lack of accurate estimation of their survival period by patients, family members, and doctors. Both doctors and patients tend to be overly optimistic about the survival period of elderly advanced cancer patients, leading to overtreatment. Therefore, assessing the risk of death for these patients and further establishing a survival period estimation model can improve the accuracy of doctors' clinical predictions of patient survival, facilitate early referral to palliative care, and promote rationalization of medical decision-making.

Clinical Trial Description

1. By searching the literature, conducting systematic reviews, and meta-analyses, we aim to uncover the prognostic factors related to death in elderly advanced cancer patients. 2. Based on evidence-based data and considering the clinical conditions of elderly advanced cancer patients in China, we will establish relevant entries for a risk assessment scale for death in elderly advanced cancer patients. By using the Delphi expert consultation evaluation method, we will finalize the assessment scale framework, laying the theoretical foundation for the establishment and validation of a death risk prediction model for elderly advanced cancer patients in China. 3. Develop a survival estimation model for elderly advanced cancer patients; through metabolomics studies and other research methods, we will investigate metabolic biomarkers related to predicting the survival period of elderly advanced cancer patients. ;

Study Design

Related Conditions & MeSH terms

Advanced Solid Tumor

Clinical Trial Details

NCT number	NCT06432283
Study type	Observational
Source	West China Hospital
Contact
Status	Active, not recruiting
Phase
Start date	May 1, 2024
Completion date	December 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06223308` - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT05508100` - Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors	Phase 1
Not yet recruiting	`NCT05515185` - B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors	Early Phase 1
Recruiting	`NCT05094804` - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Completed	`NCT02836600` - A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT04890613` - Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation	Phase 1
Recruiting	`NCT04390737` - Evaluate the Safety and Clinical Activity of HH2853	Phase 1/Phase 2
Recruiting	`NCT05981703` - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT06007482` - A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1
Completed	`NCT04108676` - Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects	Phase 1
Recruiting	`NCT05798611` - Study of ART0380 in Patients With Biologically Selected Solid Tumors	Phase 2
Recruiting	`NCT05076396` - PM14 Administered Intravenously to Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT06054932` - Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors	Phase 1
Recruiting	`NCT06008366` - A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04825392` - A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT04242199` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT06365918` - Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis	Phase 1
Recruiting	`NCT05569057` - A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma	Phase 1
Recruiting	`NCT05443126` - A Study of EP0031 in Patients With Advanced RET-altered Malignancies	Phase 1/Phase 2
Recruiting	`NCT05461287` - Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors	Phase 1